öλÔÓéÀֵǼÈë¿ÚÏÂÔØ

µ¼Ê¦ÐÕÃû£ºËï»ÝÁ¦
ÐÔ±ð£º
ÈËÆøÖ¸Êý£º228

ËùÊôԺУ£º¹ãÖÝÖÐÒ½Ò©´óѧ
ËùÊôԺϵ£º901µÚËÄÁÙ´²Ò½Ñ§Ôº
Ö°³Æ£º½ÌÊÚ
µ¼Ê¦ÀàÐÍ£ºË¶µ¼/²©µ¼
ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£º
Ñо¿ÁìÓò£º ÂýÐÔÉöÔಡµÄÖÐÎ÷Ò½·ÀÖÎ
Ñо¿ÁìÓò£º ÂýÐÔÉöÔಡµÄÖÐÎ÷Ò½·ÀÖÎ [ÊÕÆð]




¸öÈ˼òÊö :
¸öÈ˼òÊö
1977Äê5Ô³öÉú£¬É½¶«×Ͳ©ÊÐÈË£¬ºº×壬ҽѧ²©Ê¿£¬¸±½ÌÊÚ£¬¸±Ö÷ÈÎҽʦ£¬²©Ê¿Ñо¿Éúµ¼Ê¦£¬ÉîÛÚÊи߲ã´ÎÈ˲Å¡£
Ö÷ÒªÈÙÓþ
¡¶ÒæÆø½â¶¾»îѪ·¨ÖÎÁÆÌÇÄò²¡Éö²¡µÄÑо¿¡·£¬ÉîÛÚÊпƼ¼½ø²½Ò»µÈ½±£¬2014Äê
¡¶ÉöË¥1ºÅ·½·ÀÖÎÂýÐÔÉöË¥µÄÁÙ´²Óë»úÀíÑо¿¡·£¬ÖйúÖÐÒ½Ò©Ñо¿´Ù½ø»á¿Æѧ¼¼Êõ½ø²½ÈýµÈ½±£¬2015Äê
¡¶ÒæÆø½â¶¾»îѪͨÂçÀàÖÐÒ©ÖÎÁÆÌÇÄò²¡Éö²¡µÄ×÷ÓûúÖÆÑо¿¡·£¬ÖлªÖÐҽҩѧ»á¿Æѧ¼¼ÊõÈýµÈ½±£¬2015Äê

¿ÆÑй¤×÷ :
¹¤×÷¾­Àú
2015/04-ÖÁ½ñ£¬¹ãÖÝÖÐÒ½Ò©´óѧµÚËÄÁÙ´²Ò½Ñ§ÔºÉö²¡¿Æ£¬¸±Ö÷ÈÎҽʦ£¬¸±½ÌÊÚ£¬²©Ê¿Ñо¿Éúµ¼Ê¦£¨ÆƸñ£©
2014/09-2015/04£¬¹ãÖÝÖÐÒ½Ò©´óѧµÚËÄÁÙ´²Ò½Ñ§ÔºÉö²¡¿Æ£¬¸±Ö÷ÈÎҽʦ£¬¸±½ÌÊÚ£¬Ë¶Ê¿Ñо¿Éúµ¼Ê¦
2013/05-2014/12£¬ÃÀ¹úµÂ¿ËÈø˹´óѧ´ïÀ­Ë¹Ð£Çø£¬Ï¸°ûºÍ·Ö×ÓÉúÎïѧϵ£¬·ÃÎÊѧÕß
2010/12-2014/09£¬¹ãÖÝÖÐÒ½Ò©´óѧµÚËÄÁÙ´²Ò½Ñ§ÔºÉö²¡¿Æ£¬¸±Ö÷ÈÎҽʦ
2009/05-2010/12£¬¹ãÖÝÖÐÒ½Ò©´óѧµÚËÄÁÙ´²Ò½Ñ§ÔºÔºÉö²¡¿Æ£¬Ö÷ÖÎҽʦ2007/01-2009/03£¬¹ãÖÝÖÐÒ½Ò©´óѧÖÐҽѧ£¬²©Ê¿ºó
ѧÊõ¼æÖ°
¹ã¶«Ê¡ÖÐÎ÷Ò½½áºÏѧ»áÉö²¡öλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»áίԱ
ÉîÛÚÊÐҽѧ»áÉöÔಡöλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»áίԱ
ÉîÛÚÊÐҽʦЭ»áÉöÔàÄÚ¿Æҽʦ·Ö»áÀíÊÂ
ÉîÛÚÊÐÖÐҽҩѧ»áÀíÊÂ
ÉîÛÚÊÐÖÐҽҩѧ»áÉö²¡öλÔÓéÀֵǼÈë¿ÚÏÂÔØίԱ»áίԱ
¿ÆÑÐÏîÄ¿
»ùÓÚmTORµ÷¿ØÏßÁ£ÌåÉúÎïºÏ³É̽ÌÖ»ÆÜμ×ÜÕ¿¹ÌÇÄò²¡ÉöÔà·Ê´óµÄ·Ö×Ó»úÖÆ£¬2017/1/1£¬¹ú¼Ò×ÔÈ»¿Æѧ»ù½ð
»ùÓÚPERKÄÚÖÊÍøÓ¦¼¤ÐźÅͨ·̽ÌÖ»ÆÜËËØÔÚÌÇÄò²¡Éö²¡ÖеĿ¹µòÍö»úÖÆ£¬2013/1/1£¬¹ú¼Ò×ÔÈ»¿Æѧ»ù½ð
ÌÇÄò²¡ºÍÌÇÄò²¡Éö²¡µÄÖÐÒ½·½Ö¤´úл×éѧ¼°¾«×¼Ò½ÁÆ̽Ë÷£¬2016/7/1£¬ÉîÛÚÊпƼ¼¼Æ»®Ñ§¿Æ²¼¾ÖÏîÄ¿
Ö÷ÒªÂÛÎÄ
SunHuili£¬WangWenjing£¬HanPengxun£¬ShaoMumin£¬SongGaofeng£¬DuHeng£¬YiTiegang£¬LiShunmin£¬AstragalosideIVamelioratesrenalinjuryindb/dbmice£¬ScientificReports£¬2016£¬6:32545
HuiliSun£¬NaGe£¬MuminShao£¬XiaoyanCheng£¬YueLi£¬ShunminLi£¬JiangangShen£¬LumbrokinaseattenuatesdiabeticnephropathythroughregulatingextracellularmatrixdegradationinStreptozotocin-induceddiabeticrats£¬DiabetesResearchandClinicalPractice£¬2013£¬100£¨1£©£º85-95
SunHL£¬SunL£¬LiYY£¬ShaoMM£¬ChengXY£¬GeN£¬LuJD£¬LiSM£¬ACE-inhibitorsuppressestheapoptosisinducedbyendoplasmicreticulumstressinrenaltubularinexperimentaldiabeticrats£¬ExperimentalandClinicalEndocrinology&Diabetes£¬2009£¬117£¨7£©£º336-344
HanPengxun£¬SunHuili£¬XuYuanzhao£¬ZengYoujia£¬YiWuyong£¬WuJia£¬ShaoMumin£¬LiShunmin£¬YiTiegang£¬Lisinoprilprotectsagainsttheadriamycinnephropathyandreversestherenalasereduction:potentialroleofrenalaseinadriamycinnephropathy£¬KidneyBloodPressRes£¬2013£¬37£¨4-5£©£º295-304
Ëï»ÝÁ¦£¬Àî˳Ãñ£¬ÉÛÄÁÃñ£¬Ò×Ìú¸Ö£¬ÐܹúÁ¼£¬³ÌСÑ࣬¸êÄÈ£¬Â¬½¨¶«£¬»ÆÜËËضÔÌÇÄò²¡´óÊóÉöÔàµÄ±£»¤×÷Óã¬ÁÙ´²ÉöÔಡÔÓÖ¾£¬2009£¬11£¨9£©£º518-520
Ëï»ÝÁ¦£¬³ÌСÑ࣬¸êÄÈ£¬Àî˳Ãñ£¬Á½ÖÖÌÇÄò²¡Éö²¡´óÊóÄ£Ð͵ĶԱÈÑо¿£¬ÖйúÒ½Ò©Ö¸ÄÏ£¬2010£¬8£¨20£©£º244-246
Ëï»ÝÁ¦£¬ËïÁÉ£¬Äô¾²£¬ÒüÅà´ï£¬ÍõÏòÑô£¬ÀîÏþÑÞ£¬³ÂÎÄ·¼£¬ÂæÄþ£¬ÓàѧÇ壬Smad7¶Ô¸ßÌǽ鵼´óÊóÉöС¹ÜÉÏƤϸ°ûת·Ö»¯ºÍ½ºÔ­¢ñºÏ³ÉµÄÓ°Ï죬ÖлªÉöÔಡÔÓÖ¾£¬2006£¬23£¨09£©£º539-544
Ëï»ÝÁ¦£¬Ëθ߷壬¸êÄÈ£¬Ò×ÎÞÓ¹£¬º«ÅôÑ«£¬ÍõÎľ²£¬Ò×Ìú¸Ö£¬Àî˳Ãñ£¬»ùÓÚÊý¾ÝÍÚ¾ò̽ÌÖÖÐÒ½±æÖÎÌØ·¢ÐÔĤÐÔÉö²¡µÄÖ¤ÖιæÂÉ£¬½­Î÷ÖÐÒ½Ò©£¬2017,48£¨6£©£º12-15
Ëï»ÝÁ¦£¬ÒüÅà´ï£¬ÀûÍ×Îôµ¥¿¹ÖÎÁÆϵͳÐÔºì°ßÀÇ´¯Ñо¿½øÕ¹£¬Öлª·çʪ²¡Ñ§ÔÓÖ¾£¬2006£¬10£¨06£©£º369-371
Ëï»ÝÁ¦£¬¸Ê»ª£¬²»Í¬Á¬ÐøÐÔѪҺ¾»»¯¼¼Êõ¶ÔÑ×Ö¢½éÖʵÄÓ°Ï죬¹úÍâҽѧ¡¤ÃÚÄòϵͳ·Ö²á£¬2003£¬23£¨4£©£º391-393
YangLiping£¬SunHuili£¬WuLemeng£¬GuoXiujuan£¬DouHongliang£¬TsoMarkOM£¬ZhaoLin£¬LiShunmin£¬BaicaleinReducesInflammatoryProcessinaRodentModelofDiabeticRetinopathy£¬InvestigativeOphthalmology&VisualScience£¬2009£¬50£¨5£©£º2319-2327
XuHua£¬ShaoMuMin£¬SunHuiLi£¬LiShunMin£¬Primarymesenchymalchondrosarcomaofthekidneywithsynchronousimplantandinfiltratingurothelialcarcinomaoftheureter£¬DiagnosticPathology£¬2012£¬£¨7£©
SunL£¬WenJH£¬SunHL£¬ShuXC£¬HuF£¬YinDC£¬YangQ£¬ZengYJ£¬SunY£¬LiuL£¬PerindoprilattenuatesrenaltubulointerstitiuminjurybyinhibitingscavengerreceptorAover-expressionindiabeticrats£¬JournalofEndocrinologicalInvestigation£¬2012£¬35£¨5£©£º511-515
µËÜ磬Ëï»ÝÁ¦£¬ÔøÓּѣ¬Ð컪£¬¹¨ÓÀ»Û£¬Àî˳Ãñ£¬¸ßÌÇÓÕµ¼µÄÈ˽ü¶ËÉöС¹ÜÉÏƤϸ°ûËðÉ˼°»úÖƵÄÑо¿£¬ÐÂÖÐÒ½£¬2014£¬46£¨01£©£º164-167
ºÎÈÕÃ÷£¬Ëï»ÝÁ¦£¬ÑîÊﶫ£¬»ÆÜËËضÔÌÇÄò²¡´óÊóÉöÔà±£»¤×÷ÓûúÖÆÑо¿½øÕ¹£¬ÐÂÖÐÒ½£¬2014£¬46£¨01£©£º184-187
ËïÁÉ£¬Ëï»ÝÁ¦£¬ÀîÏþÑÞ£¬ÍõÏòÑô£¬ËïÑÞÑÞ£¬ÓàѧÇ壬¸ßÌÇͨ¹ýת»¯Éú³¤Òò×ÓÒÀÀµÍ¾¾¶½éµ¼ÉöС¹ÜÉÏƤϸ°û-¼¡ÏËάĸϸ°ûת·Ö»¯¼°¢ñÐͽºÔ­ºÏ³ÉµÄ»úÖÆ£¬ÖйúÌÇÄò²¡ÔÓÖ¾£¬2009£¬17£¨6£©£º443-446
ËïÁÉ£¬Ëï»ÝÁ¦£¬ÀîÏþÑÞ£¬ÍõÏòÑô£¬³ÂÎÄ·¼£¬ÂæÄþ£¬ËïÑÞÑÞ£¬¶­ÐãÇ壬ÓàѧÇ壬Smad7¶ÔÖÕÄ©ÆÚÌÇ»ù»¯²úÎï½éµ¼´óÊóÉöС¹ÜÉÏƤϸ°ûת·Ö»¯¼°¢ñÐͽºÔ­ºÏ³ÉµÄÓ°Ï죬ÖлªÄÚ·ÖÃÚ´úлÔÓÖ¾£¬2007£¬23£¨6£©£º544-548
º«ÅôÑ«£¬Ò×ÎÞÓ¹£¬Ëï»ÝÁ¦£¬Îâ¼Î£¬µËÑåÑ壬ÖÜê¿£¬ÔøÓּѣ¬Àî˳Ãñ£¬Ò×Ìú¸Ö£¬ÄÏÑó²Î¶Ô°¢Ã¹ËØÉö²¡´óÊóÉöÔà±£»¤×÷Óõijõ²½Ñо¿£¬ÖйúÖÐÎ÷Ò½½áºÏÉö²¡ÔÓÖ¾£¬2013£¬14£¨11£©£º963-965
ÉÛÄÁÃñ£¬Ð컪£¬Ëï»ÝÁ¦£¬³ÌСÑ࣬¸êÄÈ£¬Àî˳Ãñ£¬ÅàßáÆÕÀû¶ÔʵÑéÐÔÌÇÄò²¡´óÊóÉöС¹ÜÉÏƤϸ°ûµòÍöµÄÓ°Ï죬°²»ÕÒ½Ò©£¬2010£¬14£¨10£©£º1131-1132
¸êÄÈ£¬Àî˳Ãñ£¬Ëï»ÝÁ¦£¬ÉÛÄÁÃñ£¬³ÌСÑ࣬ÐܹúÁ¼£¬Ò×ÎÞÓ¹£¬Ö£Òåºî£¬µØÁú¶ÔÌÇÄò²¡Éö²¡´óÊóÉöÔà±£»¤×÷ÓõÄÑо¿£¬ÉϺ£ÖÐÒ½Ò©ÔÓÖ¾£¬2010£¬44£¨6£©£º103-105
Àî¿­£¬º«ÅôÑ«£¬Ëï»ÝÁ¦£¬Ò×ÎÞÓ¹£¬ÐìÔµîÈ£¬ÔøÓּѣ¬Îâ¼Î£¬Àî˳Ãñ£¬Ò×Ìú¸Ö£¬ÀµÅµÆÕÀû¶Ôµ°°×ÄòÓÕµ¼ÉöС¹ÜÉÏƤϸ°ûÄÚÖÊÍøÓ¦¼¤Ïà¹ØµòÍöµÄ×÷Óã¬ÖлªÉöÔಡÔÓÖ¾£¬2015£¬31£¨8£©£º610-614
ÍõÎľ²£¬¸êÄÈ£¬¹ùά¼Ó£¬Ëï»ÝÁ¦£¬Ò×Ìú¸Ö£¬Àî˳Ãñ£¬Îı¾ÍÚ¾òÌÇÄò²¡Éö²¡ÁÙ´²ÊÔÑéÖÐÒ½ÕïÁÆÌص㣬ÖйúʵÑé·½¼ÁѧÔÓÖ¾£¬2016£¬22£¨06£©£º210-215
¸êÄÈ£¬¹ùά¼Ó£¬Ñ£¬Ëï»ÝÁ¦£¬Ò×Ìú¸Ö£¬Àî˳Ãñ£¬»ùÓÚÊý¾ÝÍÚ¾òÀî˳ÃñÖÎÁÆÂýÐÔÉöÔಡÓÃÒ©¹æÂɼ°ÌصãÑо¿£¬¹ú¼ÊÖÐÒ½ÖÐÒ©ÔÓÖ¾£¬2017£¬39£¨4£©£º326-334
¸êÄÈ£¬¹ùά¼Ó£¬Ñ£¬Ëï»ÝÁ¦£¬Ò×Ìú¸Ö£¬Àî˳Ãñ£¬Êý¾ÝÍÚ¾ò¡¶ÁÙÖ¤Ö¸ÄÏÒ½°¸¡·Ö×ÕͲ¡ÓÃÒ©¹æÂÉ£¬ÊÀ½çÖÐÒ½Ò©£¬2016£¬11£¨7£©£º1351-1356
ËïÁÉ£¬ÓàѧÇ壬ףʤÀÉ£¬³ÂÎÄ·¼£¬ÀîÏþÑÞ£¬¼ÖÕ¼¾ü£¬ÍõÐÀ£¬ñ¼Ï×È¶­ÐãÇ壬Ëï»ÝÁ¦£¬AGEs¶ÔÉöС¹ÜÉÏƤϸ°ûת·Ö»¯¡¢1ÐͽºÔ­ºÏ³É¼°smadÐźÅͨ·µÄÓ°Ï죬Öйú²¡ÀíÉúÀíÔÓÖ¾£¬2006£¬22£¨12£©£º2429-2433

½ÌÓý±³¾° :
2003/09-2006/06£¬ÖÐɽ´óѧÉöÄÚ¿ÆöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£¬»ñ²©Ê¿Ñ§Î»
2000/09-2003/06£¬ÖØÇìÒ½¿Æ´óѧÉöÄÚ¿ÆöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£¬»ñ˶ʿѧλ
1994/09-1999/06£¬Î«·»Ò½Ñ§ÔºÁÙ´²Ò½Ñ§öλÔÓéÀֵǼÈë¿ÚÏÂÔØ£¬»ñѧʿѧλ